Latest Insider Transactions at Adverum Biotechnologies, Inc. (ADVM)
This section provides a real-time view of insider transactions for Adverum Biotechnologies, Inc. (ADVM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adverum Biotechnologies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adverum Biotechnologies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 30
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
85,800
+3.65%
|
$600,600
$7.15 P/Share
|
|
Jul 18
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
80,718
+3.57%
|
$726,462
$9.11 P/Share
|
|
Jul 17
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
135,546
+6.06%
|
$948,822
$7.75 P/Share
|
|
Feb 07
2024
|
Lupher, Jr. Mark L. |
BUY
Open market or private purchase
|
Direct |
130,000
+50.0%
|
$130,000
$1.35 P/Share
|
|
Feb 07
2024
|
James Paul Scopa |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$100,000
$1.35 P/Share
|
|
Sep 15
2023
|
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
6,201
-5.77%
|
$6,201
$1.54 P/Share
|
|
Jun 07
2023
|
Linda M Rubinstein CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$100,000
$1.45 P/Share
|
|
Mar 15
2023
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
SELL
Open market or private sale
|
Direct |
41,239
-5.62%
|
$0
$0.78 P/Share
|
|
Mar 15
2023
|
Peter Soparkar CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
13,360
-4.78%
|
$0
$0.78 P/Share
|
|
Mar 15
2023
|
Brigit Riley Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,299
-5.85%
|
$0
$0.78 P/Share
|
|
Sep 19
2022
|
Richard Beckman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,272
-9.86%
|
$4,272
$1.07 P/Share
|
|
Sep 19
2022
|
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
6,058
-11.23%
|
$6,058
$1.07 P/Share
|
|
Sep 19
2022
|
Peter Soparkar CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
13,305
-4.64%
|
$13,305
$1.07 P/Share
|
|
Sep 19
2022
|
Brigit Riley Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,266
-5.77%
|
$7,266
$1.07 P/Share
|
|
Sep 19
2022
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
SELL
Open market or private sale
|
Direct |
41,082
-5.35%
|
$41,082
$1.07 P/Share
|
|
Sep 14
2022
|
Richard Beckman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+41.67%
|
-
|
|
Sep 14
2022
|
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
33,333
+38.2%
|
-
|
|
May 23
2022
|
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER |
BUY
Open market or private purchase
|
Direct |
20,000
+49.26%
|
$0
$0.84 P/Share
|
|
May 17
2022
|
Richard Beckman Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$0
$0.82 P/Share
|
|
May 17
2022
|
Rupert D'Souza Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+32.41%
|
$0
$0.83 P/Share
|
|
May 16
2022
|
Dawn Svoronos |
BUY
Open market or private purchase
|
Direct |
30,000
+37.5%
|
$0
$0.85 P/Share
|
|
May 13
2022
|
Rupert D'Souza Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+47.96%
|
$0
$0.86 P/Share
|
|
Apr 20
2022
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
BUY
Open market or private purchase
|
Direct |
25,000
+3.17%
|
$25,000
$1.11 P/Share
|
|
Apr 19
2022
|
Peter Soparkar CHIEF OPERATING OFFICER |
BUY
Open market or private purchase
|
Direct |
21,925
+3.63%
|
$21,925
$1.14 P/Share
|
|
Dec 09
2021
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
BUY
Open market or private purchase
|
Direct |
14,323
+1.91%
|
$14,323
$1.85 P/Share
|
|
Dec 08
2021
|
Peter Soparkar CHIEF OPERATING OFFICER |
BUY
Open market or private purchase
|
Direct |
25,000
+8.81%
|
$25,000
$1.91 P/Share
|
|
Dec 08
2021
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
BUY
Open market or private purchase
|
Direct |
10,677
+1.46%
|
$10,677
$1.79 P/Share
|
|
Nov 15
2021
|
James Paul Scopa |
SELL
Open market or private sale
|
Indirect |
50,000
-93.75%
|
$100,000
$2.18 P/Share
|
|
Sep 30
2021
|
Julie Clark Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,766
-2.81%
|
$9,532
$2.17 P/Share
|
|
Aug 06
2021
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
BUY
Grant, award, or other acquisition
|
Direct |
680,000
+49.05%
|
-
|
|
Aug 06
2021
|
Peter Soparkar CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
220,000
+48.81%
|
-
|
|
Aug 06
2021
|
Angela Thedinga Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|
|
Aug 06
2021
|
Julie Clark Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+41.45%
|
-
|
|
Mar 31
2021
|
Dawn Svoronos |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$200,000
$10.02 P/Share
|
|
Mar 24
2021
|
Patrick Machado |
BUY
Open market or private purchase
|
Direct |
10,000
+10.19%
|
$90,000
$9.92 P/Share
|
|
Mar 24
2021
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
BUY
Open market or private purchase
|
Direct |
10,000
+27.55%
|
$90,000
$9.88 P/Share
|
|
Feb 09
2021
|
Leone D Patterson President and CFO |
SELL
Open market or private sale
|
Direct |
12,533
-5.68%
|
$175,462
$14.12 P/Share
|
|
Jan 15
2021
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
BUY
Open market or private purchase
|
Direct |
8,600
+34.55%
|
$94,600
$11.53 P/Share
|
|
Jan 15
2021
|
Patrick Machado |
BUY
Open market or private purchase
|
Direct |
10,000
+11.34%
|
$110,000
$11.52 P/Share
|
|
Dec 14
2020
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Direct |
12,783
+40.45%
|
-
|